Seer reports Q3 EPS (33c), consensus (40c)

Reports Q3 revenue $.4.16M, consensus $4.30M, Added Panome Bio to Centers of Excellence program to deliver innovative multi-omics services Demonstrated value of Proteograph Product Suite through increased customer publications available on bioRxiv Received ISO 27001 certification for increased information security and cybersecurity standards; ISO 13485 certification for quality management and to enable the utilization of products in FDA submissions Ended the quarter with $380.8 million of cash, cash equivalents and investments “Our team made progress during the third quarter to drive adoption of the Proteograph Product Suite despite the ongoing macroeconomic headwinds impacting our customers,” said Omid Farokhzad, CEO and President. “It is encouraging to see more customer manuscripts move through the peer-review process. I am confident that as more third-party data and publications demonstrate the power of our differentiated technology, we will see increasing adoption of our technology.”